상세 보기
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen
WEB OF SCIENCE
39SCOPUS
46초록
The purpose of this study was to determine the activity and safety of docetaxel plus cisplatin as second-line chemotherapy for advanced gastric cancer. This trial included patients who had failed first-line chemotherapy with a 5-fluorouracil regimen within I year before their enrollment. After registration, patients were treated with docetaxel intravenously at a dose of 60 mg/m(2) given over 1 hour followed by cisplatin 60 mg/m(2) given over 2 hours. The treatment was continued every 3 weeks until disease progression or unacceptable toxicity was detected. Forty-three patients were registered and 41 were assessable for response. Seven partial responses were observed (17.1% of the "evaluable" patients; 95% confidence interval [CI], 0-29) with a median response duration of 3.9 months. Stable disease was documented in 2 cases (4.9%). The median survival was 5.8 months (95% Cl, 3.4-8.3), resulting in a I-year survival rate of 23%. Tolerance was acceptable, with the main toxicity being neutropenia. The authors conclude that second-line chemotherapy with docetaxel plus cisplatin for advanced gastric cancer is feasible with an acceptable toxicity level.
키워드
- 제목
- Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen
- 저자
- Park, SH; Kang, WK; Lee, HR; Park, J; Lee, KE; Lee, SH; Park, JO; Kim, K; Kim, WS; Chung, CW; Im, YH; Lee, MH; Park, CH; Park, K
- 발행일
- 2004-10
- 유형
- Article
- 권
- 27
- 호
- 5
- 페이지
- 477 ~ 480
- 언어
- ENG
- 출판사
- Lippincott Williams & Wilkins Ltd.
- 발행국가
- 미국
- 분량
- 4 페이지
- ISSN
- E 1537-453X
P 0277-3732